OBJECTIVES: Valve-sparing aortic root replacement (VSARR) is recommended for patients with aortic root dilatation and preserved aortic valve cusp morphology. The durability of VSARR in Marfan patients has been questioned. The aim of our study was to establish the longterm outcomes of VSARR in Marfan patients. RESULTS: Early mortality was 0.96%, and long-term survival was 91% at 10 years and 76% at 20 years in Marfan patients. Marfan patients had a significantly better survival compared to non-Marfan patients (P < 0.0001). Freedom from aortic-valve reoperation was 86% at 10 years and 80% at 20 years in Marfan patients. The reoperation rate was similar in Marfan and non-Marfan patients (P = 0.60). Morphological perioperative features (untreated prolapse, commissural plasty, cusp plasty and graft size mismatch) predicted long-term mortality (P = 0.0054). Graft size mismatch and untreated prolapse predicted structural valve deterioration (both P < 0.0001). Long-term valve function in event-free survivors was excellent [mean gradient 4.2 (2.9-6.9), 98% aortic regurgitation < _ mild]. There were no valverelated thromboembolic or bleeding events. The endocarditis rate was 0.96%. Only 17% of the patients were on oral anticoagulants during the follow-up.
INTRODUCTION
Valve-sparing aortic root replacement (VSARR) operations were developed 20 years ago to preserve the aortic valve in patients with aortic root aneurysms. Current guidelines recommend aortic valve reimplantation or aortic root remodelling with annuloplasty in young patients with tricuspid aortic valve morphology and aortic root aneurysm [1] . In patients with connective tissue disease, however, the long-term durability of VSARR has been questioned [2] [3] [4] . This study summarizes our data on VSARR in patients with Marfan disease using the original reimplantation technique [5, 6] over a period of more than 20 years.
METHODS

Patients
Between 1993 and 2015, 582 patients underwent VSARR at our institution using the original reimplantation technique (David I) [5, 6] . Of these patients, 104 had Marfan disease [7] (see the CONSORT diagram in the Supplementary Material, Fig. S1 ). Patients who underwent other types of VSARR were excluded from the study. Preoperative data are provided in Table 1 and  Supplementary Material, Table S1 . The retrospective study was performed according to the Declaration of Helsinki and approved by the ethics committee. The consent for data acquisition and follow-up analysis was obtained from all patients.
Surgical technique
We have used the original technique of aortic valve reimplantation first described by Tirone E. David (David I) [5, 6, 8] . A detailed description of our technique is provided in the Supplementary Material, and it has been published recently [9] .
Follow-up
Patients were followed up with computed tomography or magnetic resonance angiography as well as yearly echocardiography by referring cardiologists and were recommended to attend regular visits at our outpatient clinic [1] . Follow-up was 98% complete (100/102). Two patients moved to other countries, and they were lost to follow-up after 1.0 and 6.4 years. Total follow-up time was 1201 patient-years (mean follow-up 12 ± 5.4 years). 
RESULTS
Preoperative data are shown in Table 1 . The primary indication for surgery was aortic root aneurysm with or without AR. A subset of patients underwent surgery for significant mitral valve disease in combination with aortic root enlargement. Impaired left ventricular (LV) function (9%) was significantly associated with high-degree valvular dysfunction [severe AR or mitral regurgitation (MR); P = 0.0010].
Intraoperative data are provided in Table 2 . More than one-third of patients underwent concomitant procedures-the most common being mitral valve surgery and aortic arch repair. Seventeen patients (16%) showed morphological risk factors for SVD.
Postoperative results are summarized in Table 3 . Postoperative echocardiography showed excellent valvular gradients (maximum gradient <15 mmHg, mean gradient <8 mmHg). In 5 patients (5%), postoperative AR was classified as mild. One of these patients was operated on for MR and aortic root enlargement, and she received a 24-mm aortic graft. She showed mild AR and mild-to-moderate aortic stenosis postoperatively. She was reoperated on postoperative day 20 and underwent mechanical aortic valve replacement. The other 4 patients had postoperative AR classified as trivial to mild. All 4 patients had an uneventful postoperative course (mean follow-up 12 ± 4 years) with good health status at last follow-up. AR had not deteriorated. Perioperative major adverse valve-related event [10] rate was 8.7%. This included 1 reoperation for SVD, 2 cardiac transplantations for cardiac failure after mitral valve repair and VSARR and 8 patients who needed re-exploration for bleeding.
Follow-up data are shown in Table 4 . Sixteen (15%) patients developed SVD. Of them, 13 (13/16 = 81%) underwent reoperation. Two (2/16 = 13%) patients who had developed mild-to-moderate AR have not yet been reoperated on due to stable clinical condition and preserved LV function. One patient (1/16 = 6%) developed moderate AR and severe MR but refused cardiac reoperation. He died of congestive heart failure during the follow-up.
Sixteen (15%) patients underwent aortic-valve reoperation 3.8 ± 4.5 years after the initial surgery. In a majority of patients, the indication for reoperation was SVD (13/16 = 81%). One (1/ 16 = 6%) patient developed a graft infection 4 years after VSARR. She received a cryopreserved homograft. Two patients (2/ 16 = 13%) underwent mitral valve repair and the David I procedure for severe MR, mild AR and aortic root aneurysm with reduced LV function. They developed postoperative cardiac failure. One patient was transplanted on postoperative day 25. Due to hyper-acute rejection, she underwent biventricular assist device implantation but died. The second patient was transplanted on postoperative day 14. She survived and underwent thoracoabdominal aortic repair 2 years later. Both patients had excellent aortic valve function at the time of transplantation. Technical issues with coronary button reimplantation were ruled out in both cases as a possible cause for cardiac failure.
Eleven patients (11%) died during the follow-up. The main cause of death was aortic events (7/11 = 63%). No patient died due to aortic valve-related complications. Event-free patients had excellent echocardiographic results at the last follow-up examination (echo follow-up 10 ± 5 years). A typical case is presented in Fig. 1 and Videos 1 and 2. Ninety percent of patients had no, trivial or mild AR with minimal average gradients [mean gradient 4.2 (2.9-6.9)].
At the follow-up, two-thirds of patients were able to work and 17% of patients were on oral anticoagulants (12% mechanical valves and 5.8% atrial fibrillation). Three patients developed stroke during the follow-up (2 during valve reinterventions and 1 with new onset atrial fibrillation). Two patients were diagnosed with transient ischaemic attacks. One bleeding event occurred (spontaneous intracranial bleeding, patient was not anticoagulated). The overall major adverse valve-related event rate at follow-up was 25%.
The Kaplan-Meier estimates are shown in Figs 2 and 3. Marfan patients had significant better survival compared to non-Marfan patients. Aortic valve reinterventions were comparable between groups (Fig. 2B) . Non-Marfan patients were significantly older, had a higher prevalence of cardiovascular risk factors and were significantly more often operated on for acute dissection (Supplementary Material, Table S1 ).
The univariate risk factor analysis is summarized in Supplementary Material, Tables S2 and S3. The multivariate analysis (Table 5) revealed obesity, intraoperative blood transfusions, rethoracotomy for bleeding and perioperative morphological risk factors for SVD as independent risk factors for long-term mortality. Independent risk factors for SVD or aortic valve reintervention were graft size mismatch and untreated cusp prolapse.
DISCUSSION
Valve-sparing aortic root operations were introduced in our clinic in 1993, shortly after the landmark study by David and Feindel [6] in 1992. Since then the original 'David I' procedure with a straight tube graft, as it was named by Craig Miller in 2003 [5] , has been the preferred technique at our institution. It has been used in Marfan and non-Marfan patients alike [11] [12] [13] [14] . Our series of Marfan patients has the longest average follow-up published so far (12 years). A total of 13 surgeons performed the procedures in this cohort, resulting in a small average caseload of <10 cases per surgeon. Compared with other series, especially the experience by David himself, this is a high number of surgeons involved in a procedure that is known to have a significant learning curve. However, the philosophy of our unit always has been to teach this groundbreaking technique to as many surgeons as possible.
Preoperative characteristics in our series were similar to that published by David [8] . However, intraoperatively there were significant differences: despite a similar preoperative body surface area of patients, our patients in average received 2-mm smaller aortic grafts (28 ± 1.4 mm). Concomitant procedures (especially aortic arch procedures) were more often performed in the Hannover group (37% vs 25% [8] ). Presumably due to this fact and the higher number of surgeons involved, the Hannover cardiopulmonary bypass and cross-clamp times were significantly longer. This would also explain the differences in early postoperative outcomes. However, an in-hospital mortality rate of 1% compares favourably against other series, considering the complexity of concomitant procedures.
Since 2013, upper hemisternotomy has become our standard approach for isolated David procedures (including aortic repair up to the proximal aortic arch). These operations are performed by dedicated aortic surgeons [9] . Only 2 patients were eligible for less invasive surgery in this series. Contraindications for less invasive access are concomitant procedures-a severely impaired LV function or anatomical features that would significantly increase cross-clamp times (e.g. horizontal aortic root and severe obesity).
We believe that straight tube grafts and Valsalva grafts are equally effective in the David procedure. Hence, straight tube grafts remain our standard prosthesis [15] . Patients with Valsalva grafts were not included in this study. Further long-term clinical studies are needed to evaluate the benefit of Valsalva grafts in the David procedure.
David described a remarkably low late mortality rate of 6.8 ± 2.9% at 15 years in his Marfan group. He recently emphasized his conservative approach to patient selection [16] . If one compares the Kaplan-Meier estimates with our data, mortality in the Hannover group starts to differ from the David's series beyond 5 years of follow-up. In both series, aortic complications were the main cause of death (approximately two-thirds of cases), and there was no aortic valve-related death. Late valve endocarditis was uncommon in both series (<1.5%). However, in our series 3 patients (3/11 = 27%) died of cardiomyopathy, which was associated with significant mitral valve disease. Two patients (19%) with impaired ventricular function and significant mitral valve disease underwent cardiac transplantation [17] . The subgroup of Marfan patients with primary mitral valve disease and cardiomyopathy was larger in our group compared to other series, and presumably it has affected long-term survival beyond 5 years of follow-up.
Compared with other series, our rate of aortic-valve reoperation was higher during long-term follow-up (14% at 10 years). A small number is related to cardiac transplantation for cardiomyopathy, which is not uncommon in Marfan disease [17] . However, as described by our group previously [14] and re-established in this series, morphological perioperative features play a significant role in long-term valvular function, even if the perioperative functional status is sufficient. Morphological valve features were integrated in a composite risk factor we defined as 'morphological risk for SVD'. Morphological risk factors for SVD were associated with long-term mortality. Graft size mismatch and untreated cusp prolapse were independent risk factors for SVD/aortic valve reintervention. We also abandoned the technique of commissural Trusler plasties due to unsatisfactory results. Significant surgical experience is needed to sufficiently address these pathologies (e.g. insufficient coaptation level, untreated prolapse and relative graft size mismatch) or decide whether a patient is eligible for VSARR or not. In summary, the higher number of aortic-valve reoperation in our series can be explained in part by the high number of surgeons who were involved and confirms the notion of a significant learning curve that is necessary to master aortic valve repair with durable longterm results, especially in patients with uncommon anatomical valve features. Long-term results of VSARR were not negatively affected by the genetic tissue disease itself, because valvular performance was similar in our Marfan and non-Marfan patients during the long-term follow-up. Morphological valve features, correct patient selection and the quality of the surgical repair therefore are the main criteria affecting outcomes. This finding should be addressed by conducting dedicated training programmes for aortic valve repair.
Long-term benefits from valve-sparing aortic root operations in comparison to mechanical valved composite graft operations are well established [16] . In our series, only 17% of patients needed oral anticoagulation after an average follow-up of 12 years. As this group of patients is prone to undergo major future aortic surgery, the less need for anticoagulation after VSARR is a significant benefit over mechanical valve replacement. There was no death related to valve-related thromboembolic or bleeding events. The risk for late endocarditis was lower than that described for artificial valve replacement and in line with previous reports [8, 16] . Patients with a technically perfect repair can enjoy long-lasting excellent valve function without anticoagulation, which positively affects quality of life and the ability to work. In our series, two-thirds of patients were still working, and a minority had retired (20%) or were unable to work (<15%).
Limitations
The retrospective design of the study is a limitation. Morphological features were combined as a composite risk factor due to the small sample size. Further assessment on these features is needed in a larger patient cohort.
CONCLUSION
Valve-sparing aortic root operations can be considered the preferred surgical approach to treat aortic root dilatation in Marfan patients with preserved valve cusp morphology. The defective connective tissue of Marfan patients does not negatively affect long-term outcomes. The long-term durability of VSARR is closely related to patient selection and surgical quality, which explains the heterogeneity of outcomes between the published series and confirms the notion of careful individual valve assessment and sufficient surgical training of these complex procedures in dedicated centres.
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